This study will identify the level of serum Riboneuclease 1 in systemic lupus patients and compare between its level in lupus nephritis and non nephritis.
Adult patients (≥18 years old) with non lupus nephritis SLE diagnosed according to the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus .
Adult patients (≥18 years old) with Lupus Nephritis classified according to the 2018 ISN/RPS classification criteria.
Patients less than 18 years old
Patients with other autoimmune diseases
Active infection and malignancy
Pregnancy and lactation
Systemic lupus patients from rheumatology outpatient clinic assuit university
Case-only
Retrospective
Not listed
Clinical Utility of Serum Ribonuclease 1(RNASE1) as a Biomarker of Lupus Nephritis.
Ribonuclease 1 (RNASE1) is a secreted endoribonuclease predominantly produced by endothelial cells and plays an essential role in the degradation of extracellular RNA \[11\]. These are suggested to promote endothelial activation, immune cell infiltration and activation, so promote inflammatory responses \[12-15\]. Since that endothelial dysfunction \& inflammatory signalling are central mechanism in LN pathogenesis, dysregulation of RNASE1 mediated extracellular RNA clearance may contribute to renal inflammatory injury, suggesting RNASE1 as a potential biomarker in LN
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
